ANF-Rho (pegfilgrastim biosimilar) / Prolong Pharma - LARVOL DELTA

ANF-Rho in the Treatment of Chronic Neutropenia (clinicaltrials.gov) - P1/2; N=0; Withdrawn; Sponsor: Prolong Pharmaceuticals; Not yet recruiting ➔ Withdrawn

Clinical • Trial withdrawal

Randomized Phase 2, Dose-finding Efficacy, Safety Study of ANF-RHO™ Versus Neulasta® in Chemotherapy-Induced Neutropenia (clinicaltrials.gov) - P2; N=9; Terminated; Sponsor: Prolong Pharmaceuticals; N=48 ➔ 9; Trial completion date: Dec 2019 ➔ May 2018; Recruiting ➔ Terminated; Trial primary completion date: Jun 2019 ➔ Apr 2018; Study redesign

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Trial termination